Mersana Therapeutics, Inc. (MRSN)
NASDAQ
Market Cap
$247.17M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
662 of 809
Rank in Industry
361 of 445
Largest Insider Buys in Sector
MRSN Stock Price History Chart
MRSN Stock Performance
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Mersana Therapeutics, Inc.
Over the last 12 months, insiders at Mersana Therapeutics, Inc. have bought $0 and sold $181,454 worth of Mersana Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Mersana Therapeutics, Inc. have bought $33M and sold $1.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,760 shares for transaction amount of $47,182 was made by Hack Andrew A. F. () on 2022‑05‑31.
List of Insider Buy and Sell Transactions, Mersana Therapeutics, Inc.
| 2024-01-16 | Sale | Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer | 10,409 0.0086% | $2.71 | $28,208 | +25.09% | |
| 2024-01-16 | Sale | Protopapas Anna | director | 29,399 0.0243% | $2.71 | $79,671 | +25.09% | |
| 2024-01-16 | Sale | DeSchuytner Brian | SVP, COO & CFO | 9,327 0.0077% | $2.71 | $25,276 | +25.09% | |
| 2024-01-16 | Sale | Carvajal Alejandra | SVP, Chief Legal Officer | 4,381 0.0036% | $2.71 | $11,873 | +25.09% | |
| 2024-01-16 | Sale | Mandelia Ashish | VP, Chief Accounting Officer | 5,025 0.0042% | $2.71 | $13,618 | +25.09% | |
| 2024-01-16 | Sale | MISRA TUSHAR | SVP, Chief Manuf. Officer | 3,357 0.0028% | $2.71 | $9,097 | +25.09% | |
| 2024-01-16 | Sale | Bala Mohan | SVP, Chief Development Officer | 3,431 0.0028% | $2.71 | $9,298 | +25.09% | |
| 2023-10-26 | Sale | Bala Mohan | SVP, Chief Development Officer | 1,912 0.0014% | $1.13 | $2,161 | +125.62% | |
| 2023-08-17 | Sale | MISRA TUSHAR | SVP, Chief Manuf. Officer | 1,908 0.0017% | $1.18 | $2,251 | +91.39% | |
| 2023-04-27 | Sale | Carvajal Alejandra | SVP, Chief Legal Officer | 3,944 0.0038% | $3.89 | $15,342 | -16.20% | |
| 2023-01-17 | Sale | Lowinger Timothy B | SVP, Chief Sci.&Tech. Off. | 6,233 0.0058% | $5.74 | $35,777 | -41.65% | |
| 2023-01-17 | Sale | Protopapas Anna | President & CEO | 17,346 0.0161% | $5.74 | $99,566 | -41.65% | |
| 2023-01-17 | Sale | DeSchuytner Brian | SVP, Chief Financial Officer | 5,131 0.0048% | $5.74 | $29,452 | -41.65% | |
| 2023-01-17 | Sale | Yang Arvin | SVP, Chief Medical Officer | 2,209 0.0021% | $5.74 | $12,680 | -41.65% | |
| 2023-01-17 | Sale | Mandelia Ashish | VP, Controller | 3,575 0.0033% | $5.74 | $20,521 | -41.65% | |
| 2023-01-17 | Sale | Carvajal Alejandra | SVP, Chief Legal Officer | 782 0.0007% | $5.74 | $4,489 | -41.65% | |
| 2023-01-17 | Sale | MISRA TUSHAR | SVP, CMO | 458 0.0004% | $5.74 | $2,629 | -41.65% | |
| 2022-12-01 | Sale | Yang Arvin | Chief Medical Officer | 5,527 0.0053% | $6.59 | $36,423 | -39.14% | |
| 2022-08-16 | Sale | MISRA TUSHAR | Chief Manufacturing Officer | 1,879 0.0019% | $7.10 | $13,341 | -11.20% | |
| 2022-05-31 | Hack Andrew A. F. | 14,760 0.0148% | $3.20 | $47,182 | +90.72% |
Insider Historical Profitability
33.04%
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer | 199329 0.1653% | $2.02 | 0 | 22 | |
| Protopapas Anna | director | 125153 0.1038% | $2.02 | 0 | 4 | |
| DeSchuytner Brian | SVP, COO & CFO | 54511 0.0452% | $2.02 | 0 | 2 | |
| Carvajal Alejandra | SVP, Chief Legal Officer | 27403 0.0227% | $2.02 | 0 | 4 | |
| Mandelia Ashish | VP, Chief Accounting Officer | 23328 0.0193% | $2.02 | 1 | 7 | <0.0001% |
| MISRA TUSHAR | SVP, Chief Manuf. Officer | 17966 0.0149% | $2.02 | 0 | 4 | |
| Bala Mohan | SVP, Chief Development Officer | 14052 0.0117% | $2.02 | 0 | 2 | |
| New Enterprise Associates 14, L.P. | 10 percent owner | 11959520 9.9182% | $2.02 | 2 | 1 | +8.86% |
| Hack Andrew A. F. | 8663673 7.1849% | $2.02 | 17 | 0 | +48.09% | |
| BARRIS PETER J | 10 percent owner | 8140138 6.7507% | $2.02 | 1 | 0 | +20.77% |
| BARRETT M JAMES | 10 percent owner | 8140138 6.7507% | $2.02 | 1 | 0 | +20.77% |
| KERINS PATRICK J | 10 percent owner | 8140138 6.7507% | $2.02 | 1 | 0 | +20.77% |
| Sonsini Peter W. | 10 percent owner | 8140138 6.7507% | $2.02 | 1 | 0 | +20.77% |
| Viswanathan Ravi | 10 percent owner | 8140138 6.7507% | $2.02 | 1 | 0 | +20.77% |
| MOTT DAVID M | director | 538599 0.4467% | $2.02 | 3 | 0 | +56.98% |
| Kaufman Michael J. | Chief Manufacturing Officer | 32622 0.0271% | $2.02 | 0 | 2 | |
| Yang Arvin | SVP, Chief Medical Officer | 30821 0.0256% | $2.02 | 0 | 3 | |
| Alleva Lawrence M | director | 2120 0.0018% | $2.02 | 2 | 0 | <0.0001% |
| Jack Eva M. | Chief Bus. Officer, Tres, Sec. | 0 0% | $2.02 | 0 | 1 | |
| BASKETT FOREST | 10 percent owner | 0 0% | $2.02 | 1 | 1 | +20.77% |
| SANDELL SCOTT D | 10 percent owner | 0 0% | $2.02 | 1 | 2 | +20.77% |
| Florence Anthony A. Jr. | 10 percent owner | 0 0% | $2.02 | 1 | 1 | +20.77% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Ecor1 Capital Llc | $86.75M | 15.83 | 19.36M | 0% | +$0 | 2.21 | |
| Vr Adviser Llc | $50.75M | 9.26 | 11.33M | 0% | +$0 | 2.47 | |
| Bain Capital Life Sciences Investors Llc | $38.81M | 7.08 | 8.66M | 0% | +$0 | 3.9 | |
| BlackRock | $36.27M | 6.62 | 8.1M | +3.21% | +$1.13M | <0.01 | |
| The Vanguard Group | $28.11M | 5.13 | 6.27M | +0.59% | +$164,783.36 | <0.01 | |
| State Street | $24.63M | 4.49 | 5.5M | +136% | +$14.19M | <0.01 | |
| Nextech Invest | $17.28M | 3.15 | 3.86M | -35.49% | -$9.51M | 2.82 | |
| Balyasny Asset Management Llc | $16.38M | 2.99 | 3.66M | -62.3% | -$27.07M | 0.04 | |
| Citadel Advisors LLC | $15.5M | 2.83 | 3.46M | +79.51% | +$6.86M | 0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $13.65M | 2.49 | 3.05M | 0% | +$0 | 0.35 | |
| Silverarc Capital Management Llc | $13.3M | 2.43 | 2.97M | -53.76% | -$15.46M | 3.92 | |
| Morgan Stanley | $13.18M | 2.41 | 2.94M | -28.83% | -$5.34M | <0.01 | |
| Woodline Partners LP | $13.15M | 2.4 | 2.93M | New | +$13.15M | 0.12 | |
| Cormorant Asset Management Lp | $11.65M | 2.13 | 2.6M | New | +$11.65M | 0.55 | |
| Geode Capital Management | $10.57M | 1.93 | 2.36M | +2.66% | +$273,696.57 | <0.01 | |
| ACUTA CAPITAL PARTNERS LLC | $9.7M | 1.77 | 2.16M | -8.59% | -$911,106.52 | 6.3 | |
| Deutsche Bank | $7.1M | 1.3 | 1.59M | +39.15% | +$2M | <0.01 | |
| Millennium Management LLC | $6.75M | 1.23 | 1.51M | -55.59% | -$8.45M | 0.01 | |
| Renaissance Technologies | $6.4M | 1.17 | 1.43M | +64.93% | +$2.52M | 0.01 | |
| JPMorgan Chase | $6.39M | 1.17 | 1.43M | +1,710.82% | +$6.04M | <0.01 | |
| 5Am Venture Management Llc | $5.85M | 1.07 | 1.3M | 0% | +$0 | 0.39 | |
| D. E. Shaw & Co. | $5.48M | 1 | 1.22M | +83.2% | +$2.49M | 0.01 | |
| Baker Bros Advisors LP | $4.87M | 0.89 | 1.09M | 0% | +$0 | 0.06 | |
| Schonfeld Group | $4.52M | 0.82 | 1.01M | -11.47% | -$585,755.41 | 0.03 | |
| Affinity Asset Advisors | $4.48M | 0.82 | 1M | 0% | +$0 | 0.8 | |
| Octagon Capital Advisors LP | $4.48M | 0.82 | 1M | New | +$4.48M | 0.59 | |
| Qube Research & Technologies | $4.3M | 0.78 | 959,695 | New | +$4.3M | 0.01 | |
| Northern Trust | $4.23M | 0.77 | 945,171 | +1.48% | +$61,667.21 | <0.01 | |
| Jacobs Levy Equity Management | $3.63M | 0.66 | 809,879 | -12.97% | -$540,861.45 | 0.02 | |
| Ally Bridge Group | $3.59M | 0.66 | 801,437 | New | +$3.59M | 2.02 | |
| Goldman Sachs | $3.01M | 0.55 | 672,607 | +362.07% | +$2.36M | <0.01 | |
| Deep Track Capital Lp | $2.6M | 0.47 | 579,674 | New | +$2.6M | 0.01 | |
| Verition Fund Management Llc | $2.53M | 0.46 | 564,163 | New | +$2.53M | 0.03 | |
| Wellington Management Company | $2.4M | 0.44 | 534,618 | New | +$2.4M | <0.0001 | |
| ClariVest Asset Management LLC | $2.11M | 0.39 | 471,848 | New | +$2.11M | 0.22 | |
| Acadian Asset Management | $2.1M | 0.38 | 468,923 | +166.72% | +$1.31M | 0.01 | |
| Atom Investors Lp | $1.97M | 0.36 | 439,232 | -43.3% | -$1.5M | 0.25 | |
| Ubs Oconnor Llc | $1.95M | 0.36 | 434,293 | -21.84% | -$543,657.06 | 0.17 | |
| Citigroup | $1.86M | 0.34 | 414,848 | +2,497.02% | +$1.79M | <0.01 | |
| Barclays | $1.83M | 0.33 | 409,218 | +169.11% | +$1.15M | <0.01 | |
| BNY Mellon | $1.7M | 0.31 | 378,737 | -2.05% | -$35,490.57 | <0.0001 | |
| Jane Street Capital | $1.66M | 0.3 | 370,633 | -0.1% | -$1,747.20 | <0.01 | |
| Rafferty Asset Management Llc | $1.65M | 0.3 | 368,434 | New | +$1.65M | 0.01 | |
| Fidelity Investments | $1.46M | 0.27 | 325,597 | -39.21% | -$940,938.52 | <0.0001 | |
| Invesco | $1.45M | 0.27 | 324,410 | +565.73% | +$1.24M | <0.0001 | |
| Monashee Investment Management LLC | $1.39M | 0.25 | 310,000 | New | +$1.39M | 0.12 | |
| Charles Schwab | $1.33M | 0.24 | 295,872 | -3.96% | -$54,656.02 | <0.0001 | |
| UBS | $1.3M | 0.24 | 289,667 | +88.98% | +$611,031.60 | <0.0001 | |
| Cubist Systematic Strategies | $1.07M | 0.2 | 239,143 | +106.77% | +$553,221.95 | 0.01 | |
| Panagora | $1.06M | 0.19 | 236,042 | -6.1% | -$68,723.19 | 0.01 |